In the KEYNOTE-604 trial, PD-L1 was retrospectively assessed using the combined positive score (CPS), defined as the number of PD-L1-staining cells divided by the total number of viable tumor cells times 100 (6). The gene discussed is CD274; the disease is neoplasm.